|
Antibody-drug conjugates (ADCs) offer enhanced precision and reduced off-target toxicity. Popular ADC targets include HER2, Trop2, Nectin4, EGFR, CD19, CD22, CD30, BCMA, and CD79b. The evolving landscape includes emerging targets like EpCAM, CD70, CD25, CD166, showing promising clinical results. Sino Biological supports the development of next-generation ADCs by offering high-quality ADC targets from multiple species for cross-species validation, along with anti-payload antibodies, FcγRs, FcRn, and other related products.
|
Biosimilar antibody binding validation (ELISA/SPR/BLI) 
